Fitzpatrick Jennifer 4
4 · Sionna Therapeutics, Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Sionna (SION) CLO Jennifer Fitzpatrick Exercises Options, Sells 10,250 Shares
What Happened
Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics (SION), exercised options for 10,250 shares and sold those 10,250 shares in the open market on March 5, 2026. The options were exercised at $6.11 per share (total exercise cost $62,628) and the shares were sold at a weighted average price of $33.86 per share for aggregate proceeds of $347,019. The sale was executed under a pre-existing Rule 10b5-1 trading plan.
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 6, 2026 (timely filing).
- Option exercise: 10,250 shares acquired at $6.11 each (total $62,628).
- Open-market sale: 10,250 shares sold at a weighted average $33.86 (total $347,019). Reported sale prices ranged from $32.56 to $34.83.
- Additional derivative line: the filing also shows a related derivative conversion/disposition entry at $0.00 (recordkeeping treatment of the exercised derivative).
- Shares owned after the transaction: not specified in the information provided in the filing.
- Footnotes: sale was automatically executed under a Rule 10b5-1 plan adopted June 5, 2025 (F1); weighted-average price disclosure and range provided (F2); the option had partial vesting (25% vested June 3, 2025) with remaining shares vesting monthly over 36 months subject to continued service (F3).
Context
This was an option exercise followed by an immediate sale of the resulting shares (a common cashless/cash exercise pattern). The sale was pre-arranged under a 10b5-1 plan, which typically schedules trades in advance and helps avoid questions about timing or intent. The filing is factual and does not indicate the insider’s motive.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-03-05$6.11/sh+10,250$62,628→ 10,250 total - Sale
Common Stock
[F1][F2]2026-03-05$33.86/sh−10,250$347,019→ 0 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F1][F3]2026-03-05−10,250→ 50,935 totalExercise: $6.11Exp: 2034-07-14→ Common Stock (10,250 underlying)
Footnotes (3)
- [F1]This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.56 to $34.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]25% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.